COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Roseanne SullivanAjay KilaruBernhard HemmerBruce Anthony Campbell CreeBenjamin M GreenbergUma KunduThomas HachVirginia DeLasHerasBrian J WardJoseph BergerPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
Based on a review of available information, the risk of more severe COVID-19 in patients receiving fingolimod or siponimod seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.
Keyphrases
- multiple sclerosis
- coronavirus disease
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- mass spectrometry
- peritoneal dialysis
- early onset
- electronic health record
- emergency department
- healthcare
- machine learning
- respiratory syndrome coronavirus
- big data
- patient reported
- social media